Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe webpage has removed significant details regarding a clinical study on the efficacy and safety of atezolizumab in combination with bevacizumab for treating Hepatocellular Carcinoma, including study design, inclusion and exclusion criteria, and treatment arms. Additionally, it has added a new EudraCT number and a revision number.SummaryDifference7%
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check71 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check86 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact for assistance.SummaryDifference0.5%
Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.